


China's innovative biopharma: Deepening integration into global pipelines



Number of innovative drug license-out deals
and total deal value in China, 2019-2025

— Number of deals — Total deal value (in billion USD)



Sources: Sinolytics research

Weekly Facts & Figures.

- **Global licensing surge:** China's innovative drug license-out deals jumped from 94 in 2024 to 157 in 2025, with disclosed deal value rising from about 51.9 billion USD to around 135.7 billion USD.
- **Policy expansion:** In 2025 and 2026, Chinese government policies began supporting not just R&D, but also commercialization and payment systems for innovative drugs, signalling a more comprehensive industry boost.
- **Resilient cooperation:** Despite new U.S. restrictions on Chinese biotech, large cross-border deals, such as Sino Biopharm's partnership with Sanofi, continued in early 2026, though compliance and risk management have become more complex.

**What
This
Means.**

"China's innovative drug sector is expanding its global role through licensing partnerships, even as geopolitical dynamics reshape how collaborations are structured."



Weiqing Zhu
Consultant

Start the conversation.



weiqing.zhu@sinolytics.de



sinolytics.de